ReviewInternational journal of ophthalmology2026
Limbal stem cell deficiency secondary to topical glaucoma medication: a scoping review.
Review in International journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This scoping review aims to focus on the association between topical anti-glaucoma medication and limbal stem cell deficiency through a comprehensive analysis from the available relevant case reports, research articles and experimental studies. By understanding the potential risks associated with long-term anti-glaucoma medication use and their impact on corneoscleral limbus, precautions can be taken to balance between the risk of glaucoma progression and limbal stem cell deficiency. All relevant publications from 2000 to 2023 were included and evidence of strong emerging potential link between topical glaucoma eyedrops and the disruption of limbal stem cell homeostasis were found. Prolong use of topical glaucoma medication with preservatives were found to have a negative effect on limbal stem cells. The frequent use of topical preservative-free prostaglandin analogues and beta-blockers, commonly prescribed for glaucoma, is associated with morphological alterations in the corneoscleral limbus. These changes appear to be mediated through an inflammatory process, leading to disruption of the corneoscleral limbal niche which eventually results in limbal stem cell deficiency. With the advancement of glaucoma surgical treatment, it is possible for glaucoma treatment to shift towards earlier surgical modality to reduce topical anti-glaucoma burden leading to limbal stem cell deficiency.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.